Clinical Trial Update: Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and immune response to the EP HIV-1090 HIV vaccine in HIV-infected adults, with completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EP HIV-1090 vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED